This article was originally published in The Gray Sheet
Shareholders approve recapitalization proposal that will create two new classes of common stock on May 5 to separately track the performance of the company's PE Biosystems Group (PEB) and Celera Genomics Group (CRA) businesses on the New York Stock Exchange. In conjunction with the move, Perkin-Elmer changes its name to PE Corporation, effective May 5
You may also be interested in...
Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.
With Warp Speed Decisions Already Made, Transitioning To Biden Admin Should Be No Trouble, Slaoui Says
As vaccines near availability, Moncef Slaoui says his full-time role at OWS may be ending. He has not met with the Biden Transition team, but notes that other Warp Speed officials have.
Strong top-line efficacy in pyruvate kinase deficiency patients who don’t receive regular transfusions looks approvable, analysts say, but Agios will await data in regularly transfused patients.